Abstract
Targeting the poly (ADP-ribose) polymerase (PARP) protein has shown therapeutic efficacy in cancers with homologous recombination (HR) deficiency due to BRCA mutations. Only small fraction of acute myeloid leukemia (AML) cells carry BRCA mutations, hence the antitumor efficacy of PARP inhibitors (PARPi) against this malignancy is predicted to be limited; however, recent preclinical studies have demonstrated that PARPi monotherapy has modest efficacy in AML, while in combination with cytotoxic chemotherapy it has remarkable synergistic antitumor effects. Immunotherapy has revolutionized therapeutics in cancer treatment, and PARPi creates an ideal microenvironment for combination therapy with immunomodulatory agents by promoting tumor mutation burden. In this review, we summarize the role of PARP proteins in DNA damage response (DDR) pathways, and discuss recent preclinical studies using synthetic lethal modalities to treat AML. We also review the immunomodulatory effects of PARPi in AML preclinical models and propose future directions for therapy in AML, including combined targeting of the DDR and tumor immune microenvironment; such combination regimens will likely benefit patients with AML undergoing PARPi-mediated cancer therapy.
Background
The poly (ADP-ribose) polymerase (PARP) protein superfamily comprises 17 members, which are encoded by different genes but share a common catalytic domain (). PARP-mediated PARylation of PARP proteins themselves, or other DNA damage response (DDR) substrates, enhances DNA damage repair and promotes the survival of proliferating cells (). The use of PARP inhibitors (PARPi) to treat BRCA1/2-mutant or homologous recombination (HR)-deficient tumors has been studied in various cancers, and is referred to as ‘synthetic lethality’ (; ; Parvin et al., 2019).
PARP enzymes have important roles in cell biology processes, including post-transcription regulation, chromatin structure stabilization, metabolism, antiviral responses, telomere maintenance, cell cycle progression, and, most importantly, the DDR (Jubin et al., 2016). To date, eight PARP family members have been demonstrated to contribute to maintenance of genome stability through promoting DNA damage repair or cell cycle regulation (Slade, 2019). Besides being involved in single-strand break repair (SSBR), PARP proteins also have key roles in double-strand break (DSB) repair (). In response to DNA damage, the PARP enzyme first localizes to damage sites via its N-terminal zinc finger domain (Langelier et al., 2011). The most important step in the repair process is the generation of PAR chains in multiple protein substrates, referred to as PARylation. Among PARP family members, PARP1 is the most abundant and responsible for generation of the majority of cellular PAR chains, while PARP2 accounts for only 5%–10% (Schreiber et al., 2006). The PARylation of multiple protein substrates leads to recruitment of DNA repair proteins to damage sites, where they mediate the repair cascade. Without appropriate PARP activity, single-strand breaks (SSBs) ultimately lead to formation of DSBs, which represent the most deleterious type of genome damage (; ; Schiewer et al., 2012).
The PARP family members, PARP1, PARP2, and PARP3, are the most widely studied in mammalian cells, because of their involvement in DNA repair activity. These proteins act as DNA damage sensors, according to different types of DNA damage, and cooperate with other mediators to repair DNA damage through activating several DNA repair pathways, such as SSBR, HR, and non-homologous end joining (NHEJ) (Hartlerode and Scully, 2009; Pardo et al., 2009). In the following section, we review the function of PARP proteins, and particularly the PARP1 enzyme, in SSB and DSB repair. We also summarize recent studies using PARPi to treat acute myeloid leukemia (AML), where the majority of AML tumors harbor wild-type BRCA1/2.
PARP enzymes in SSBR
In mammalian cells, there are thousands of DNA breaks arose per cell each day. In response to those DNA lesions, which include SSB and DSB, cells have evolved a series of DNA repair systems to maintain genome integrity. Endogenous factor-induced SSB can be repaired by PARP1-mediated base excision repair (BER) (). In this process, PARP1 PARylates itself and a series of substrates to promote the accumulation of DNA repair factors at single-stranded DNA (ssDNA) sites to mediate repair progression (; Ronson et al., 2018). In detail, upon PARylation, PARP1 collaborates with proteins, including DNA polymerase β, DNA ligase III, XRCC1, ALC1, and PNKP, to complete DNA break repair (Figure 1) (; Hanzlikova et al., 2017; ; Hewitt et al., 2021; Paes Dias et al., 2021).
FIGURE 1
PARP enzyme in DSB repair
When SSBs are left unrepaired, or repaired incorrectly, they will convert into DSBs, which are the most dangerous type of lesion and threaten genome integrity, potentially leading to cancer development. Mammalian cells have involved two repair pathways which includes HR pathway and NHEJ pathway to repair the DSBs (Figure 1) (San Filippo et al., 2008; Hartlerode and Scully, 2009; Pardo et al., 2009). The phase of the cell cycle determines which pathway is used to repair the DNA lesions, NHEJ is active throughout the cell cycle, while HR only occurs in S or G2 phase (Huertas et al., 2008; ; Orthwein et al., 2014). In response to DSB, PARP1 is among the proteins that respond earliest to DSBs and, once PARP1 is activated by DSB, it recruits initial mediators to DSB sites.
NHEJ pathways can be divided into classical and alternative types. Classical NHEJ (cNHEJ) always repairs breaks occurring in the G0/G1 phase, during which PARP1 PARylates DNA-PKCs and PARylation of PARP1 itself recruits the KU70-KU80 complex, which promotes DNA ligase IV and the XRCC4/XRCC4-like factors (XLF) complex to DNA ends, to mediate their ligation (Lieber, 2010; ; ). Notably, before ligation, DNA ends require processing by the nucleases, Artemis and APLF (). Compared with cNHEJ, alternative NHEJ (aNHEJ) is active in the S and G2 phases of the cell cycle (Wyatt et al., 2016; Yu et al., 2020). The first step of this pathway is initiated by PARP1-mediated localization of the MRN-CtIP complex on the DNA ends, then CtIP acts with MRN to mediate the excision of DNA ends, to expose ssDNA microhomology sequences (Xie et al., 2009; ). Following this step, PARP1 combines with MRN and Pol θ to promote alignment of DNA single strands through microhomology sequences (Kent et al., 2015). For DNA regions without 3′homology sequences, ends are digested by XRCC1 and XPF (Okano et al., 2005). Overall, PARP1 is indispensable, and importantly interacts with various other factors, to complete both the cNHEJ and aNHEJ repair processes.
Compared with NHEJ repair, in which DNA ends are directly ligated and always recognized in an error-prone manner, HR is highly accurate and uses the sister chromatid as template to complete DNA repair (Juhasz et al., 2018; Ranjha et al., 2018). This characteristic restricts HR to occurring only in S and G2 phase, when sister chromatids are available (Liu and Huang, 2014). The first step of HR is initiation of DNA end resection, which is mediated by the MRN complex and BRCA1 (; ; Zhao et al., 2020). The role of PARP1 in this process is to recruit and activate the MRN complex and BRCA1 to the DSB ends (Li and Yu, 2013). However, there have also been reports that BRCA1 localization to DSB ends is independent of PARP1 (Wu et al., 2009). DNA end resection leads to subsequent generation of ssDNA, which is first bound by RPA, followed by recruitment and loading of RAD51 on to the ssDNA to complete the repair process (; Prakash et al., 2015). DNA end resection is a fundamental step in HR and its efficiency is determined by PARP1, which PARylates various substrates, including CtIP, the MRN complex, and BRCA1 (Moison et al., 2021; Luedeman et al., 2022). Notably, BRCA1 and 53BP1 play opposing roles in determining which DSB repair pathway (HR or cNHEJ) occurs ().
Rationale for targeting PARP in AML
Sequence data demonstrate that PARP family genes alteration is rare in patients with AML; however, mutations and copy number alterations of DDR genes, such as, ATM, ATR, CHEK1, CHEK2, RAD51, and PALB2, have been detected, leading to HR pathway dysregulation in patients with AML (cBioPortal for Cancer Genomics. http://www.cbioportal.org/.). PALB2 deletion predicts HR defects and confers cancer cell sensitivity to PARPi (; ; ). Further, there is mounting evidence that PARP family members have key roles in regulating gene transcription, promoting protein stability, and modulating chromosome structure (Wacker et al., 2007; Ji and Tulin, 2010; Krishnakumar and Kraus, 2010). Dysregulation of gene transcription or chromosomes can result in errors in the DDR. Collectively, this led to the realization that targeting PARP may provide an ideal strategy for AML patients with known genetic background such as different karyotypic aberrations (Tyner et al., 2018). In the following sections, we summarize preclinical and clinical studies of different PARPi for treatment of AML (Table 1).
TABLE 1
| Inhibitor | Combination with | Phase | Status | NCT number |
|---|---|---|---|---|
| Talazoparib | Topotecan/gemcitabine | Phase I | Rrecruiting | NCT05101551 |
| Talazoparib | Decitabine | Phase I and II | Completed | NCT02878785 |
| Olaparib | Monotherapy | Phase II | Active | NCT03953898 |
| Veliparib | Temozolomide | Phase I | Active | NCT01139970 |
| Talazoparib | Monotherapy | Phase I | Completed | NCT01399840 |
Ongoing clinical trials of the use of PARP inhibitors in AML.
Immunotherapy for AML.
Olaparib
As we known, SSB frequently occurs in proliferating cells, and efficient repair of SSB is dependent on PARP activity. The mechanism underlying PARPi activity can be divided into two aspects: inhibition of PARP enzyme activity and tapping PARP itself on the damage sites. Olaparib inhibits four members of the PARP family, PARP1 to PARP4, and is the PARPi that has been most extensively studied in the context of AML (). In a previous study, patient-derived AML cells carrying AML1-ETO or PML-RARα mutations were demonstrated to be sensitive to olaparib. In contrast, MLL-AF9 or E2A-PBX subtype AML cells were unresponsive to olaparib. Mechanistic analysis showed that AML1-ETO or PML-RARα fusion oncogenes can inhibit HR activity through suppressing several HR-associated genes in AML cells, thus leading to olaparib sensitivity (Figure 2) (). In another study, olaparib inhibited XRCC1 loading onto DNA damage sites and prevented BER repair, while combination treatment with olaparib and decitabine induced synthetic lethality effects in AML cells (Orta et al., 2014). WEE1 inhibitor has been shown to sensitize cancer cells to cytotoxic agents, and WEE1 inhibition can reduce HR activity by directly constraining BRCA2 (Kausar et al., 2015). Garcia et al. showed that the WEE1 inhibitor, AZD1775, combined with olaparib, induced synergistic antitumor effects in an AML model (). Mechanistic analysis further demonstrated that AZD1775 suppressed HR and enhanced DNA damage, thus sensitizing AML cells to PARPi. Mutations of FLT3 have been detected in up to 23% of patients with AML and confer a poor prognosis. In a recent study, the FLT3 kinase inhibitor, AC220, was used to treat FLT3-positive AML cells, and was found to suppress expression of a subset of DNA repair proteins, thus causing synthetic lethal effects when administered with olaparib. Combined use of AC220 and olaparib eliminated FLT3-positive quiescent and proliferating leukemia stem cells, as well as reducing leukemia initiating cells (Maifrede et al., 2018). NF-κB is reported to mediate resistance of AML cells to DNA damage agents (). Ding et al. showed that simultaneous targeting of NF-κB and PARP with olaparib resulted in substantial cell killing (Li et al., 2019). IDH1/2 mutation is reported to occur in 20% of patients with AML and inhibits DNA damage repair genes, conferring sensitivity of cancer cells to PARPi (Sulkowski et al., 2017; ). In a recent paper, the authors showed that IDH1/2-mutated AML cells were sensitive to olaparib or talazoparib, and the study further supported the clinical trial of olaparib monotherapy or combined with daunorubicin in AML patients with IDH1/2-mutation (Figure 2) (Molenaar et al., 2018). Furthermore, olaparib is reported to be effective against IDH1/2-mutated AML or MDS in patient-derived xenograft models, but not in corresponding wild-type AML/MDS models (). Together, these studies support the translation of PARPi for application in patients with AML with IDH1/2-mutation. KDM6A loss-of-function mutation was reported to be associated with conventional chemotherapy response in patients with AML, and olaparib treatment has demonstrated antitumor efficacy in AML with KDM6A mutation. Co-targeting PARP and BCL2 using olaparib in AML showed superior therapeutic effects (). Further, vitamin C can inhibit AML progression through enhancing TET2 activity; however, single agent modality treatment was not curative in this disease. Nevertheless, a recent study demonstrated that treatment with vitamin C combined with olaparib elicited strong synergistic effects in blocking AML self-renewal in murine and human AML models (). Together, these results demonstrate the promising therapeutic potential of olaparib in AML, either as single agent or combination with other inhibitors.
FIGURE 2
Rucaparib and niraparib
Rucaparib and niraparib are small molecular inhibitors administered orally. Rucaparib targets PARP1 to PARP4 (Syed, 2017), while niraparib is designed to target PARP1 and PARP2 for cancer therapy (Shen et al., 2015). Few studies have tested the efficacy of rucaparib or niraparib in AML. One investigation using rucaparib with the cytotoxic agent, 5-FU, to treat acute leukemias detected strong synergistic antitumor efficacy against AML (). Comparably, a triple combination of niraparib, decitabine, and HDACi synergistically induced DNA damage and promoted cell death in AML cell lines, the effects of this triple combination on primary leukemic cells were also confirmed (Valdez et al., 2018).
Talazoparib
Talazoparib has the most potent PARP trapping activity compared with other PARP inhibitors (Murai et al., 2012). There are several studies that test the efficacy of talazoparib against AML. Talazoparib or APE1 inhibitor were demonstrated to induce critical antileukemic effects against selected primary CD34+ AML samples, and further experiments demonstrated that low dose talazoparib and APE1 inhibitor treatment enhanced the efficacy of decitabine against AML (Kohl et al., 2019). The cohesin complex plays an important role in DNA chromosome maintenance and transcription regulation (Jeppsson et al., 2014). Recurrent somatic alteration of the cohesin complex is frequent in AML, and cohesin-mutant cells are reported to be highly dependent on DNA damage repair and replication networks; hence, AML cells with cohesin complex mutations are sensitive to talazoparib (Tothova et al., 2021). PARP1 expression levels are correlated with prognosis in patients with cancer, and high PARP1 expression predicts poor survival of patients with AML, while combined treatment using talazoparib and NL101 resulted in strong synergistic effects against AML (Li et al., 2018). Mechanistic analysis showed enhanced cell apoptosis, G2 cell cycle arrest, and DNA damage in response to talazoparib and NL101 combination therapy. Further, DNA methyltransferase inhibitors substantially enhanced the efficacy of talazoparib against AML, both in vitro and in vivo (Muvarak et al., 2016). Moreover, in a recent clinical trial, the same research group conducted a dose escalating study of DNMTi, decitabine, combined with talazoparib for treatment of patients with AML who were previously treated or not treated with decitabine. The results indicated that, combined of decitabine with talazoparib is well-tolerated and that pharmacodynamic effects can be expected in responsive patients (). BACT1, a key enzyme in branched-chain amino acid metabolism, has important roles in cancer progression; however, the oncogenic role of BACT1 in AML has not been fully elucidated. A recent study demonstrated that BACT1 can decrease DDR activity and sensitize AML cells to talazoparib, both in vitro and in vivo (Pan et al., 2024).
Immunotherapy for AML
Over the past 4 decades, the standard treatment option for patients with AML is combination of chemotherapy. Fewer than one-third of patients with AML are responsive to core chemotherapy, meaning that most are unresponsive, and highlighting the need to identify new therapeutic approaches to satisfactorily treat more patients with this condition (). Hematopoietic stem cell transplantation (alloHSCT) represents the most promising strategy for curing patients with AML; however, very few patients are eligible for this approach and, after alloHSCT, most develop tumor relapse, leading to particularly poor clinical outcomes (; ). A key reason underlying AML relapse is tumor cell escape from immune cell surveillance or attack (Zeiser and Vago, 2019; Tettamanti et al., 2022). In this section, we summarize recently developed novel strategies, particularly involving immune checkpoint blockade, for AML treatment, and discuss the obstacles to identifying targets for AML immunotherapy.
Mechanisms of immune evasion in AML
Multiple mechanisms are implicated in regulating AML immune evasion, including leukemia-intrinsic and -extrinsic evasion processes (Figure 3) (Vago and Gojo, 2020; Tettamanti et al., 2022). The first is that AML blasts can inhibit the expression of antigen presentation molecules and overexpress immune inhibitory molecules, such as PD-L1 and Cal-9 (Kikushige et al., 2010; Kikushige and Miyamoto, 2015; Taghiloo and Asgarian-Omran, 2021). Further, the bone marrow niche can release reactive oxygen species, indoleamine 2,3-dioxygenase 1, TGF-β, arginase, and extracellular vesicles in the AML microenvironment, which can suppress the cytotoxic effects of T and NK cells, as well as promoting regulatory T cell and myeloid-derived suppressor cell (MDSC) activity (; ; Lu and Gabrilovich, 2012; Sun et al., 2015; Pyzer et al., 2017; ; Yang et al., 2020). Moreover, the AML microenvironment can promote M1-type macrophage conversion into M2-type macrophages, which promote cancer development (). Together, these intrinsic and extrinsic mechanisms cooperate to induce tumor cell immune evasion, thereby mediating therapy resistance.
FIGURE 3
Immune checkpoint blockade inhibitors in AML
The efficacies of multiple immune checkpoint inhibitors in the treatment of AML have been studied (Table 2). An early investigation explored the effect of ipilimumab against hematologic malignancies, and found that a dose of 10 mg/kg induced promising responses in 5/12 patients with AML, among which 3 patients had responses lasting more than 1 year (). The combined effects of ipilimumab combined with decitabine are now being explored in the clinic in both pre- and post-alloHSCT patients, in comparison with those of monotherapy. Hypomethylating agents (HMAs) have been shown to affect the immune system, and a combination of HMA with PD-1/PD-L1 inhibition has been evaluated in AML in several studies, with a subset of patients found to respond to the combination regimen (). Furthermore, a triple combination of azacytidine, nivolumab, and ipilimumab led to improved outcomes, but with more frequent immune-related side effects (NCT02397720). Pembrolizumab, another PD-1 inhibitor, was evaluated for use in patients with AML in combination with decitabine or azacytidine, and the results were similar to those of combination therapy with azacitidine and nivolumab () (NCT02845297). Further, targeting the PD-1/PD-L1 interaction using anti-PD-1 or -PD-L1 antibodies showed limited effects in patients with AML, while the combination of PD-1 or PD-L1 inhibitors and chemotherapy enhanced treatment efficacy in patients newly-diagnosed with AML.
TABLE 2
| Inhibitor | Combination with | Phase | Status | NCT number |
|---|---|---|---|---|
| Camrelizumab | Decitabine | Phase II | Unknown | NCT04353497 |
| Nivolumab | Monotherapy | Phase II | Active | NCT02275533 |
| Atezolizumab | Guadecitabine | Phase I/II | Active | NCT03935361 |
| Atezolizumab | Hu5F9-G4 | Phase I | Terminated | NCT03922477 |
| Atezolizumab | Guadecitabine | Phase I | Completed | NCT02892318 |
| Nivolumab | Decitabine/Venetoclax | Phase I | Active | NCT04277442 |
| Atezolizumab | BL8040 | Phase I/II | Terminated | NCT03154827 |
| Nivolumab/Relatlimab | Azacitidine | Phase II | Recruiting | NCT04913922 |
| Pembrolizumab | Monotherapy | Phase II | Completed | NCT02708641 |
| Pembrolizumab | Azacitadine | Phase II | Completed | NCT02845297 |
| Pembrolizumab | Decitabine | Phase I/II | Completed | NCT02996474 |
| Nivolumab | Cytarabine | Phase II | Terminated | NCT03381118 |
| Pembrolizumab | Azacitidine | Phase II | Recruiting | NCT03769532 |
| Pembrolizumab | Fludarabine/Melphalan | Phase II | Completed | NCT02771197 |
| Pembrolizumab | Azacitidine/Venetoclax | Phase II | Active | NCT04284787 |
| Pembrolizumab | Cytarabine/idarubicin | Phase II | Recruiting | NCT04214249 |
| Nivolumab/Azacitidine | ipilimumab | Phase II | Completed | NCT02397720 |
| Nivolumab | azacitidine | Phase II/III | Active | NCT03092674 |
| Pembrolizumab | cytarabine | Phase II | Active | NCT02768792 |
| Nivolumab | Idarubicin/cytarabine | Phase I/II | Completed | NCT02464657 |
| Pembrolizumab | Venetoclax/Decitabine | Phase I | Recruiting | NCT03969446 |
| Pembrolizuma | AMG330 | Phase I | Terminated | NCT04478695 |
| Atezolizumab | gilteritinib | Phase I/II | Completed | NCT03730012 |
| Ipilimumab | Decitabine | Phase I | Active | NCT02890329 |
| Nivolumab/Ipilimumab | Monotherapy | Phase I | Active | NCT03600155 |
| Nivolumab | cyclophosphamide | Phase II | Completed | NCT03417154 |
| Ipilimumab | Monotherapy | Phase I | Active | NCT03912064 |
| Ipilimumab | Monotherapy | Phase I | Completed | NCT01757639 |
| Nivolumab | 5-azacytidine | Phase I/II | Active | NCT03825367 |
Clinical studies of the use of ICIs as monotherapy or combination therapy for AML.
Immunomodulatory effects of PARP inhibitor in AML
Conventionally, PARPi are considered to exert their functions through enzyme inhibition and PARP trapping. In addition to a direct effect on the DDR, there are increasing reports that PARP inhibition can modulate immune responses in the tumor microenvironment (Pham et al., 2021; Kornepati et al., 2022). PARP inhibition can enhance innate immunity through various mechanisms, leading to the development of combination treatments with PARPi and immunotherapy for the treatment of cancers, including solid tumors and hematologic malignancies (; Kim et al., 2020). Dysregulation of the DDR occurs through various mechanisms, including enhancement of tumor mutational burden (TMB) by PARP inhibition, leading to generation of neoantigens, which can promote the cytotoxic effects of T cells (). However, recent studies have demonstrated that PARP inhibition activates stimulators of inhibitory genes, further enhancing PD-L1 expression on the surface of tumor cells (Figure 4) (Sen et al., 2019). Collectively, PARP inhibition by enhanced tumor immunogenicity creates an ideal microenvironment for combination treatment of cancer using PARPi and immune checkpoint inhibitors.
FIGURE 4
In hematologic malignancy, the combination of PARP inhibitor with immune checkpoint inhibitors warrants further exploration. In a previous study, genotoxic stress such as PARP inhibition induced expression of NKG2D ligands in AML cells, and NKG2D ligands bind to NKG2D receptors in immune cells, including NK and cytotoxic T cells (). Binding of NKG2D ligands to the NKG2D receptor on the surface of NK cells can exert their cytotoxic effects, leading to NK cell-mediated cell killing (Figure 4). Paczulla et al. showed that PARP1 enzyme can repress expression of NKG2D ligands on the surface of AML cells. Therefore, treatment using PARPi, followed by transfer of NK cells, can substantially suppress leukemogenesis in AML patient-derived xenograft models (Paczulla et al., 2019). Moreover, PARPi can sensitize AML cells to TRAIL (a key NK cell effector molecule) through activating Fas and DR5 (Meng et al., 2014). Taken together, these findings open new avenues for treatment of AML using PARPi in combination with immunomodulatory agents.
Conclusion and future directions
Patients with AML often achieve tumor remission after standard therapy, but invariably die of relapse via various mechanisms, such as the presence of leukemic stem cells (Stavropoulou et al., 2016). Preclinical studies are increasingly identifying and investigating novel therapeutics with potential to eradicate bulk AML cells and AML stem cells. PARPi, which are widely used to treat breast and ovarian cancers carrying BRCA mutations, are now emerging as novel therapeutics for acute leukemia with selected genetic backgrounds; for example, they are effective against IDH1/2- or AML1-ETO-mutant AML cells (Figure 2). Nonetheless, PARPi appear to have limited activity as single agents in treatment of relapsed or refractory AML cells. Therefore, combination therapy has emerged and is anticipated to expand the efficacy of PARPi against AML. Indeed, several studies have tested the efficacy of combination therapy with PARPi and different small molecules, such as antibody-drug conjugates, FLT3 inhibitor, DNMTi, and HDACi, in AML cells.
As HR-related genes are rarely mutated in AML, the therapeutic efficacy of PARP inhibitors is limited in this disease. Expanding the utility of PARP inhibitor is an urgent need in the clinic and will satisfy more AML patients. ‘BRCAness’ is termed as a subset of tumors that lack BRCA mutations but show other characteristics that can phenocopy BRCA mutation. Owing to competent HR activity in AML cells, inducing ‘BRCAness’ phenotype might have synthetic lethality effects with PARP inhibitors in treating AML. Indeed, various studies have identified strategies that induce ‘BRCAness’ to treat AML. A newest study indicated that targeting splicing factor SF3B1 resulted in impaired DNA damage response and sensitized AML cells to PARP inhibitor (Wheeler et al., 2024). Epigenetic dysregulation contributes to AML pathogenesis. Furthermore, targeting KDM6 demethylase sensitizes AML cells to PARP inhibitor. Besides, targeting epigenetic factors such as BRD4 have shown synergistic antitumor effects with PARP inhibitor in a variety of cancer treatment, such combination therapy needs further exploration in the treatment AML (Yang et al., 2017; Sun et al., 2018). Together, future directions, both computational or experimental methodologies, should focus on identifying cancer-specific synthetic lethality interactions to extent the treatment efficacy of PARP inhibitor in AML.
Over the past decade, identifying suitable immune therapeutics to suppress leukemic cells and their progenitor cells have been a focus of cancer research. Unfortunately, the immunosuppressive microenvironment of acute leukemia supports leukemic cell evasion of immune cell attack. Therefore, considering the complexity of the AML tumor microenvironment, a rational combination of immunotherapy with complementary strategies can be predicted to prevent tumor escape and eradicate AML cells, without increased side effects. In this context, understanding the key role of the tumor microenvironment in hampering therapeutic efficacy and modulating toxicity warrants greater attention.
Future challenges for AML therapeutics include increasing treatment efficacy and regulating immune escape mechanisms generated by the tumor microenvironment. Furthermore, precise identification of the mechanisms of immune evasion in individual patients with AML has potential to inform development of personalized immunotherapy, according to specific immune signatures. Since the combination of an immune checkpoint inhibitor and PARPi induce robust antitumor immune responses, particularly against cancers with high levels of HR deficiency, investigating novel immune therapy combinations may be beneficial to more patients with acute leukemia, regardless of their genetic background. Further, evaluation of treatment efficacy and safety in preclinical and clinical studies, and identifying predictive biomarkers for patient selection, should be priorities.
Statements
Author contributions
XB: Writing–original draft, Writing–review and editing. WL: Conceptualization, Software, Writing–review and editing. KY: Conceptualization, Project administration, Software, Writing–review and editing. CS: Writing–original draft, Writing–review and editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by West Anhui university (WGKQ2021077, WGKQ2023010).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbbottsR.WilsonD. M.3rd (2017). Coordination of DNA single strand break repair. Free Radic. Biol. Med.107, 228–244. 10.1016/j.freeradbiomed.2016.11.039
2
Al-MataryY. S.BotezatuL.OpalkaB.HonesJ. M.LamsR. F.ThivakaranA.et al (2016). Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica101, 1216–1227. 10.3324/haematol.2016.143180
3
AltmeyerM.MessnerS.HassaP. O.FeyM.HottigerM. O. (2009). Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res.37, 3723–3738. 10.1093/nar/gkp229
4
AmeJ. C.SpenlehauerC.de MurciaG. (2004). The PARP superfamily. Bioessays26, 882–893. 10.1002/bies.20085
5
AnandR.RanjhaL.CannavoE.CejkaP. (2016). Phosphorylated CtIP functions as a Co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. Mol. Cell.64, 940–950. 10.1016/j.molcel.2016.10.017
6
AureliusJ.ThorenF. B.AkhianiA. A.BruneM.PalmqvistL.HanssonM.et al (2012). Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. Blood119, 5832–5837. 10.1182/blood-2011-11-391722
7
BaerM. R.KoganA. A.BentzenS. M.MiT.LapidusR. G.DuongV. H.et al (2022). Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia. Clin. Cancer Res.28, 1313–1322. 10.1158/1078-0432.CCR-21-3729
8
BoilaL. D.GhoshS.BandyopadhyayS. K.JinL.MurisonA.ZengA. G. X.et al (2023). KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia37, 751–764. 10.1038/s41375-023-01833-z
9
BrabsonJ. P.LeesangT.YapY. S.WangJ.LamM. Q.FangB.et al (2023). Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia. Cell. Rep.42, 112027. 10.1016/j.celrep.2023.112027
10
BryantH. E.PetermannE.SchultzN.JemthA. S.LosevaO.IssaevaN.et al (2009). PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J.28, 2601–2615. 10.1038/emboj.2009.206
11
BryantH. E.SchultzN.ThomasH. D.ParkerK. M.FlowerD.LopezE.et al (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature434, 913–917. 10.1038/nature03443
12
BuntingS. F.CallenE.WongN.ChenH. T.PolatoF.GunnA.et al (2010). 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell.141, 243–254. 10.1016/j.cell.2010.03.012
13
CaldecottK. W. (2008). Single-strand break repair and genetic disease. Nat. Rev. Genet.9, 619–631. 10.1038/nrg2380
14
CarreiraS.PortaN.Arce-GallegoS.SeedG.Llop-GuevaraA.BianchiniD.et al (2021). Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial. Cancer Discov.11, 2812–2827. 10.1158/2159-8290.CD-21-0007
15
CasorelliI.TenediniE.TagliaficoE.BlasiM. F.GiulianiA.CrescenziM.et al (2006). Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes. Leukemia20, 1978–1988. 10.1038/sj.leu.2404376
16
ChangH. H. Y.PannunzioN. R.AdachiN.LieberM. R. (2017). Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat. Rev. Mol. Cell. Biol.18, 495–506. 10.1038/nrm.2017.48
17
ChapmanJ. R.TaylorM. R.BoultonS. J. (2012). Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell.47, 497–510. 10.1016/j.molcel.2012.07.029
18
ChenH.LisbyM.SymingtonL. S. (2013). RPA coordinates DNA end resection and prevents formation of DNA hairpins. Mol. Cell.50, 589–600. 10.1016/j.molcel.2013.04.032
19
ChenJ. K.LinW. L.ChenZ.LiuH. W. (2018). PARP-1-dependent recruitment of cold-inducible RNA-binding protein promotes double-strand break repair and genome stability. Proc. Natl. Acad. Sci. U. S. A.115, E1759–E1768. 10.1073/pnas.1713912115
20
ChristopherM. J.PettiA. A.RettigM. P.MillerC. A.ChendamaraiE.DuncavageE. J.et al (2018). Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med.379, 2330–2341. 10.1056/NEJMoa1808777
21
Cruz-GarciaA.Lopez-SaavedraA.HuertasP. (2014). BRCA1 accelerates CtIP-mediated DNA-end resection. Cell. Rep.9, 451–459. 10.1016/j.celrep.2014.08.076
22
CurtiA.TrabanelliS.SalvestriniV.BaccaraniM.LemoliR. M. (2009). The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood113, 2394–2401. 10.1182/blood-2008-07-144485
23
CurtinN. J.SzaboC. (2020). Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat. Rev. Drug Discov.19, 711–736. 10.1038/s41573-020-0076-6
24
Dall’OlioF. G.MarabelleA.CaramellaC.GarciaC.AldeaM.ChaputN.et al (2022). Tumour burden and efficacy of immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol.19, 75–90. 10.1038/s41571-021-00564-3
25
DaverN.Garcia-ManeroG.BasuS.BodduP. C.AlfayezM.CortesJ. E.et al (2019). Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov.9, 370–383. 10.1158/2159-8290.CD-18-0774
26
DavidsM. S.KimH. T.BachireddyP.CostelloC.LiguoriR.SavellA.et al (2016). Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med.375, 143–153. 10.1056/NEJMoa1601202
27
DavisA. J.ChenD. J. (2013). DNA double strand break repair via non-homologous end-joining. Transl. Cancer Res.2, 130–143. 10.3978/j.issn.2218-676X.2013.04.02
28
DeminA. A.HirotaK.TsudaM.AdamowiczM.HailstoneR.BrazinaJ.et al (2021). XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Mol. Cell.81, 3018–3030.e5. 10.1016/j.molcel.2021.05.009
29
DillonK. M.BekeleR. T.SztupinszkiZ.HanlonT.RafieiS.SzallasiZ.et al (2022). PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer. NPJ Precis. Oncol.6, 49. 10.1038/s41698-022-00291-7
30
DingL.KimH. J.WangQ.KearnsM.JiangT.OhlsonC. E.et al (2018). PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer. Cell. Rep.25, 2972–2980. 10.1016/j.celrep.2018.11.054
31
El-KhamisyS. F.MasutaniM.SuzukiH.CaldecottK. W. (2003). A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res.31, 5526–5533. 10.1093/nar/gkg761
32
Escribano-DiazC.OrthweinA.Fradet-TurcotteA.XingM.YoungJ. T.TkacJ.et al (2013). A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol. Cell.49, 872–883. 10.1016/j.molcel.2013.01.001
33
EspositoM. T.ZhaoL.FungT. K.RaneJ. K.WilsonA.MartinN.et al (2015). Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat. Med.21, 1481–1490. 10.1038/nm.3993
34
EsteyE. H. (2014). Acute myeloid leukemia: 2014 update on risk-stratification and management. Am. J. Hematol.89, 1063–1081. 10.1002/ajh.23834
35
FalzacappaM. V.RonchiniC.FarettaM.IacobucciI.Di RoraA. G.MartinelliG.et al (2015). The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias. Mol. Cancer Ther.14, 889–898. 10.1158/1535-7163.MCT-14-0276
36
FaraoniI.AloisioF.De GabrieliA.ConsalvoM. I.LavorgnaS.VosoM. T.et al (2018). The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-κB activation. Cancer Lett.423, 127–138. 10.1016/j.canlet.2018.03.008
37
FarmerH.McCabeN.LordC. J.TuttA. N.JohnsonD. A.RichardsonT. B.et al (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434, 917–921. 10.1038/nature03445
38
FritzC.PortwoodS. M.PrzespolewskiA.WangE. S. (2021). PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Rev.45, 100696. 10.1016/j.blre.2020.100696
39
GarciaT. B.SnedekerJ. C.BaturinD.GardnerL.FosmireS. P.ZhouC.et al (2017). A small-molecule inhibitor of WEE1, AZD1775, synergizes with olaparib by impairing homologous recombination and enhancing DNA damage and apoptosis in acute leukemia. Mol. Cancer Ther.16, 2058–2068. 10.1158/1535-7163.MCT-16-0660
40
GasserS.OrsulicS.BrownE. J.RauletD. H. (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature436, 1186–1190. 10.1038/nature03884
41
GbyliR.SongY.LiuW.GaoY.BianconG.ChandhokN. S.et al (2022). In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia36, 1313–1323. 10.1038/s41375-022-01536-x
42
GoswamiM.GuiG.DillonL. W.LindbladK. E.ThompsonJ.ValdezJ.et al (2022). Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J. Immunother. Cancer10, e003392. 10.1136/jitc-2021-003392
43
GrelletyT.PeyraudF.SevenetN.TredanO.DohollouN.Barouk-SimonetE.et al (2020). Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. Ann. Oncol.31, 822–823. 10.1016/j.annonc.2020.03.283
44
HanY.JinF.XieY.LiuY.HuS.LiuX. D.et al (2019). DNAPKcs PARylation regulates DNAPK kinase activity in the DNA damage response. Mol. Med. Rep.20, 3609–3616. 10.3892/mmr.2019.10640
45
HansrivijitP.GaleR. P.BarrettJ.CiureaS. O. (2019). Cellular therapy for acute myeloid Leukemia - current status and future prospects. Blood Rev.37, 100578. 10.1016/j.blre.2019.05.002
46
HanzlikovaH.GittensW.KrejcikovaK.ZengZ.CaldecottK. W. (2017). Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res.45, 2546–2557. 10.1093/nar/gkw1246
47
HartlerodeA. J.ScullyR. (2009). Mechanisms of double-strand break repair in somatic mammalian cells. Biochem. J.423, 157–168. 10.1042/BJ20090942
48
HewittG.BorelV.Segura-BayonaS.TakakiT.RuisP.BellelliR.et al (2021). Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD. Mol. Cell.81, 767–783.e11. 10.1016/j.molcel.2020.12.006
49
HuertasP.Cortes-LedesmaF.SartoriA. A.AguileraA.JacksonS. P. (2008). CDK targets Sae2 to control DNA-end resection and homologous recombination. Nature455, 689–692. 10.1038/nature07215
50
JeppssonK.KannoT.ShirahigeK.SjogrenC. (2014). The maintenance of chromosome structure: positioning and functioning of SMC complexes. Nat. Rev. Mol. Cell. Biol.15, 601–614. 10.1038/nrm3857
51
JiY.TulinA. V. (2010). The roles of PARP1 in gene control and cell differentiation. Curr. Opin. Genet. Dev.20, 512–518. 10.1016/j.gde.2010.06.001
52
JubinT.KadamA.JariwalaM.BhattS.SutariyaS.GaniA. R.et al (2016). The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival. Cell. Prolif.49, 421–437. 10.1111/cpr.12268
53
JuhaszS.ElbakryA.MathesA.LobrichM. (2018). ATRX promotes DNA repair synthesis and sister chromatid exchange during homologous recombination. Mol. Cell.71, 11–24. 10.1016/j.molcel.2018.05.014
54
KausarT.SchreiberJ. S.KarnakD.ParselsL. A.ParselsJ. D.DavisM. A.et al (2015). Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair. Neoplasia17, 757–766. 10.1016/j.neo.2015.09.006
55
KentT.ChandramoulyG.McDevittS. M.OzdemirA. Y.PomerantzR. T. (2015). Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase θ. Nat. Struct. Mol. Biol.22, 230–237. 10.1038/nsmb.2961
56
KikushigeY.MiyamotoT. (2015). Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia. Oncology89 (Suppl. 1), 28–32. 10.1159/000431062
57
KikushigeY.ShimaT.TakayanagiS.UrataS.MiyamotoT.IwasakiH.et al (2010). TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell. Stem Cell.7, 708–717. 10.1016/j.stem.2010.11.014
58
KimC.WangX. D.YuY. (2020). PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. Elife9, e60637. 10.7554/eLife.60637
59
KohlV.FlachJ.NaumannN.BrendelS.KleinerH.WeissC.et al (2019). Antileukemic efficacy in vitro of talazoparib and APE1 inhibitor III combined with decitabine in myeloid malignancies. Cancers (Basel)11, 1493. 10.3390/cancers11101493
60
KornepatiA. V. R.BoydJ. T.MurrayC. E.SaifetiarovaJ.de la Pena AvalosB.RogersC. M.et al (2022). Tumor intrinsic PD-L1 promotes DNA repair in distinct cancers and suppresses PARP inhibitor-induced synthetic lethality. Cancer Res.82, 2156–2170. 10.1158/0008-5472.CAN-21-2076
61
KrishnakumarR.KrausW. L. (2010). PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol. Cell.39, 736–749. 10.1016/j.molcel.2010.08.014
62
LangelierM. F.PlanckJ. L.RoyS.PascalJ. M. (2011). Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: structural and functional insights into DNA-dependent PARP-1 activity. J. Biol. Chem.286, 10690–10701. 10.1074/jbc.M110.202507
63
LiD.LuoY.ChenX.ZhangL.WangT.ZhuangY.et al (2019). NF-κB and poly (ADP-ribose) polymerase 1 form a positive feedback loop that regulates DNA repair in acute myeloid leukemia cells. Mol. Cancer Res.17, 761–772. 10.1158/1541-7786.MCR-18-0523
64
LiM.YuX. (2013). Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylation. Cancer Cell.23, 693–704. 10.1016/j.ccr.2013.03.025
65
LiX.LiC.JinJ.WangJ.HuangJ.MaZ.et al (2018). High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMedicine38, 47–56. 10.1016/j.ebiom.2018.11.025
66
LieberM. R. (2010). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu. Rev. Biochem.79, 181–211. 10.1146/annurev.biochem.052308.093131
67
LiuT.HuangJ. (2014). Quality control of homologous recombination. Cell. Mol. Life Sci.71, 3779–3797. 10.1007/s00018-014-1649-5
68
LuT.GabrilovichD. I. (2012). Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment. Clin. Cancer Res.18, 4877–4882. 10.1158/1078-0432.CCR-11-2939
69
LuedemanM. E.StroikS.FengW.LuthmanA. J.GuptaG. P.RamsdenD. A. (2022). Poly(ADP) ribose polymerase promotes DNA polymerase theta-mediated end joining by activation of end resection. Nat. Commun.13, 4547. 10.1038/s41467-022-32166-7
70
MaifredeS.Nieborowska-SkorskaM.Sullivan-ReedK.DasguptaY.Podszywalow-BartnickaP.LeB. V.et al (2018). Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood132, 67–77. 10.1182/blood-2018-02-834895
71
MengX. W.KohB. D.ZhangJ. S.FlattenK. S.SchneiderP. A.BilladeauD. D.et al (2014). Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. J. Biol. Chem.289, 20543–20558. 10.1074/jbc.M114.549220
72
MoisonC.ChagraouiJ.CaronM. C.GagneJ. P.CoulombeY.PoirierG. G.et al (2021). Zinc finger protein E4F1 cooperates with PARP-1 and BRG1 to promote DNA double-strand break repair. Proc. Natl. Acad. Sci. U. S. A.118, e2019408118. 10.1073/pnas.2019408118
73
MolenaarR. J.RadivoyevitchT.NagataY.KhurshedM.PrzychodzenB.MakishimaH.et al (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin. Cancer Res.24, 1705–1715. 10.1158/1078-0432.CCR-17-2796
74
MuraiJ.HuangS. Y.DasB. B.RenaudA.ZhangY.DoroshowJ. H.et al (2012). Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res.72, 5588–5599. 10.1158/0008-5472.CAN-12-2753
75
MuvarakN. E.ChowdhuryK.XiaL.RobertC.ChoiE. Y.CaiY.et al (2016). Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell.30, 637–650. 10.1016/j.ccell.2016.09.002
76
OkanoS.LanL.TomkinsonA. E.YasuiA. (2005). Translocation of XRCC1 and DNA ligase IIIalpha from centrosomes to chromosomes in response to DNA damage in mitotic human cells. Nucleic Acids Res.33, 422–429. 10.1093/nar/gki190
77
OrtaM. L.HoglundA.Calderon-MontanoJ. M.DominguezI.Burgos-MoronE.VisnesT.et al (2014). The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions. Nucleic Acids Res.42, 9108–9120. 10.1093/nar/gku638
78
OrthweinA.Fradet-TurcotteA.NoordermeerS. M.CannyM. D.BrunC. M.StreckerJ.et al (2014). Mitosis inhibits DNA double-strand break repair to guard against telomere fusions. Science344, 189–193. 10.1126/science.1248024
79
PaczullaA. M.RothfelderK.RaffelS.KonantzM.SteinbacherJ.WangH.et al (2019). Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature572, 254–259. 10.1038/s41586-019-1410-1
80
Paes DiasM.TripathiV.van der HeijdenI.CongK.ManolikaE. M.BhinJ.et al (2021). Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol. Cell.81, 4692–4708.e9. 10.1016/j.molcel.2021.09.005
81
PanJ.WangY.HuangS.MaoS.LingQ.LiC.et al (2024). High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response. J. Mol. Med. Berl.102, 415–433. 10.1007/s00109-023-02409-1
82
PardoB.Gomez-GonzalezB.AguileraA. (2009). DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell. Mol. Life Sci.66, 1039–1056. 10.1007/s00018-009-8740-3
83
ParvinS.Ramirez-LabradaA.AumannS.LuX.WeichN.SantiagoG.et al (2019). LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell.36, 237–249. 10.1016/j.ccell.2019.07.007
84
PhamM. M.NgoiN. Y. L.PengG.TanD. S. P.YapT. A. (2021). Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer7, 958–970. 10.1016/j.trecan.2021.05.004
85
PrakashR.ZhangY.FengW.JasinM. (2015). Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol.7, a016600. 10.1101/cshperspect.a016600
86
PyzerA. R.StroopinskyD.RajabiH.WashingtonA.TagdeA.CollM.et al (2017). MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood129, 1791–1801. 10.1182/blood-2016-07-730614
87
RanjhaL.HowardS. M.CejkaP. (2018). Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes. Chromosoma127, 187–214. 10.1007/s00412-017-0658-1
88
RonsonG. E.PibergerA. L.HiggsM. R.OlsenA. L.StewartG. S.McHughP. J.et al (2018). PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat. Commun.9, 746. 10.1038/s41467-018-03159-2
89
San FilippoJ.SungP.KleinH. (2008). Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem.77, 229–257. 10.1146/annurev.biochem.77.061306.125255
90
SchiewerM. J.GoodwinJ. F.HanS.BrennerJ. C.AugelloM. A.DeanJ. L.et al (2012). Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov.2, 1134–1149. 10.1158/2159-8290.CD-12-0120
91
SchreiberV.DantzerF.AmeJ. C.de MurciaG. (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell. Biol.7, 517–528. 10.1038/nrm1963
92
SenT.RodriguezB. L.ChenL.CorteC. M. D.MorikawaN.FujimotoJ.et al (2019). Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov.9, 646–661. 10.1158/2159-8290.CD-18-1020
93
ShenY.Aoyagi-ScharberM.WangB. (2015). Trapping poly(ADP-ribose) polymerase. J. Pharmacol. Exp. Ther.353, 446–457. 10.1124/jpet.114.222448
94
SladeD. (2019). Mitotic functions of poly(ADP-ribose) polymerases. Biochem. Pharmacol.167, 33–43. 10.1016/j.bcp.2019.03.028
95
StavropoulouV.KasparS.BraultL.SandersM. A.JugeS.MorettiniS.et al (2016). MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell.30, 43–58. 10.1016/j.ccell.2016.05.011
96
SulkowskiP. L.CorsoC. D.RobinsonN. D.ScanlonS. E.PurshouseK. R.BaiH.et al (2017). 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci. Transl. Med.9, eaal2463. 10.1126/scitranslmed.aal2463
97
SunC.YinJ.FangY.ChenJ.JeongK. J.ChenX.et al (2018). BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell.33, 401–416. 10.1016/j.ccell.2018.01.019
98
SunH.LiY.ZhangZ. F.JuY.LiL.ZhangB. C.et al (2015). Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int. J. Hematol.102, 579–586. 10.1007/s12185-015-1865-2
99
SyedY. Y. (2017). Rucaparib: first global approval. Drugs77, 585–592. 10.1007/s40265-017-0716-2
100
TaghilooS.Asgarian-OmranH. (2021). Immune evasion mechanisms in acute myeloid leukemia: a focus on immune checkpoint pathways. Crit. Rev. Oncol. Hematol.157, 103164. 10.1016/j.critrevonc.2020.103164
101
TettamantiS.PievaniA.BiondiA.DottiG.SerafiniM. (2022). Catch me if you can: how AML and its niche escape immunotherapy. Leukemia36, 13–22. 10.1038/s41375-021-01350-x
102
TothovaZ.ValtonA. L.GorelovR. A.VallurupalliM.Krill-BurgerJ. M.HolmesA.et al (2021). Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight6, e142149. 10.1172/jci.insight.142149
103
TynerJ. W.TognonC. E.BottomlyD.WilmotB.KurtzS. E.SavageS. L.et al (2018). Functional genomic landscape of acute myeloid leukaemia. Nature562, 526–531. 10.1038/s41586-018-0623-z
104
VagoL.GojoI. (2020). Immune escape and immunotherapy of acute myeloid leukemia. J. Clin. Investig.130, 1552–1564. 10.1172/JCI129204
105
ValdezB. C.LiY.MurrayD.LiuY.NietoY.ChamplinR. E.et al (2018). Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget9, 3908–3921. 10.18632/oncotarget.23386
106
WackerD. A.RuhlD. D.BalagamwalaE. H.HopeK. M.ZhangT.KrausW. L. (2007). The DNA binding and catalytic domains of poly(ADP-ribose) polymerase 1 cooperate in the regulation of chromatin structure and transcription. Mol. Cell. Biol.27, 7475–7485. 10.1128/MCB.01314-07
107
WheelerE. C.MartinB. J. E.DoyleW. C.NeaherS.ConwayC. A.PittonC. N.et al (2024). Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Sci. Transl. Med.16, eade2774. 10.1126/scitranslmed.ade2774
108
WuJ.HuenM. S.LuL. Y.YeL.DouY.LjungmanM.et al (2009). Histone ubiquitination associates with BRCA1-dependent DNA damage response. Mol. Cell. Biol.29, 849–860. 10.1128/MCB.01302-08
109
WyattD. W.FengW.ConlinM. P.YousefzadehM. J.RobertsS. A.MieczkowskiP.et al (2016). Essential roles for polymerase theta-mediated end joining in the repair of chromosome breaks. Mol. Cell.63, 662–673. 10.1016/j.molcel.2016.06.020
110
XieA.KwokA.ScullyR. (2009). Role of mammalian Mre11 in classical and alternative nonhomologous end joining. Nat. Struct. Mol. Biol.16, 814–818. 10.1038/nsmb.1640
111
YangL.ZhangY.ShanW.HuZ.YuanJ.PiJ.et al (2017). Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci. Transl. Med.9, eaal1645. 10.1126/scitranslmed.aal1645
112
YangY.LiC.LiuT.DaiX.BazhinA. V. (2020). Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation. Front. Immunol.11, 1371. 10.3389/fimmu.2020.01371
113
YuW.LescaleC.BabinL.Bedora-FaureM.Lenden-HasseH.BaronL.et al (2020). Repair of G1 induced DNA double-strand breaks in S-G2/M by alternative NHEJ. Nat. Commun.11, 5239. 10.1038/s41467-020-19060-w
114
ZeiserR.VagoL. (2019). Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood133, 1290–1297. 10.1182/blood-2018-10-846824
115
ZhaoF.KimW.KloeberJ. A.LouZ. (2020). DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells. Exp. Mol. Med.52, 1705–1714. 10.1038/s12276-020-00519-1
Summary
Keywords
PARP, DNA repair, AML, immuotherapy, synergisctic effects
Citation
Bian X, Liu W, Yang K and Sun C (2024) Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia. Front. Pharmacol. 15:1421816. doi: 10.3389/fphar.2024.1421816
Received
23 April 2024
Accepted
25 July 2024
Published
08 August 2024
Volume
15 - 2024
Edited by
Andrei Leitao, University of São Paulo, Brazil
Reviewed by
Amitava Sengupta, Indian Institute of Chemical Biology (CSIR), India
Ashlesha Kadam, Wake Forest University, United States
Updates
Copyright
© 2024 Bian, Liu, Yang and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chuanbo Sun, scb19781979@126.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.